Last synced on 2 May 2025 at 11:05 pm

Everolimus Immunoassay

Page Type
Product Code
Definition
To quantify everolimus in whole blood.
Physical State
NA
Technical Method
immunoassay
Target Area
IVD
Regulation Medical Specialty
Toxicology
Review Panel
Toxicology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
862.3840
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 862.3840 Sirolimus test system

§ 862.3840 Sirolimus test system.

(a) Identification. A sirolimus test system is a device intended to quantitatively determine sirolimus concentrations in whole blood. Measurements are used as an aid in management of transplant patients receiving therapy with sirolimus.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Sirolimus Test Systems.” See § 862.1(d) for the availability of this guidance document.

[69 FR 58259, Sept. 30, 2004]

Everolimus Immunoassay

Page Type
Product Code
Definition
To quantify everolimus in whole blood.
Physical State
NA
Technical Method
immunoassay
Target Area
IVD
Regulation Medical Specialty
Toxicology
Review Panel
Toxicology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
862.3840
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 862.3840 Sirolimus test system

§ 862.3840 Sirolimus test system.

(a) Identification. A sirolimus test system is a device intended to quantitatively determine sirolimus concentrations in whole blood. Measurements are used as an aid in management of transplant patients receiving therapy with sirolimus.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Sirolimus Test Systems.” See § 862.1(d) for the availability of this guidance document.

[69 FR 58259, Sept. 30, 2004]